Creative Biolabs

Global Lipid Nanoparticle Manufacturing Market 2023-2035: Partnerships Surge in Lipid Nanoparticle Manufacturing as Moderna Collaborates with IBM for Cutting-Edge LNPs - ResearchAndMarkets.com

Retrieved on: 
Monday, February 12, 2024
Technology, Biotechnology, Nanotechnology, Health, Molecule, CMO, Infection, Growth, RNA, Phospholipid, Liposome, Solubility, Organization, Absorption, Integration, Therapy, Type, Levidian Nanosystems, Small RNA, Ionization, DNA, Partnership, Creative Biolabs, CMOS, Permeability, Sphingolipid, CDMO, SaRNA, Dicarboxylic acid, Antigen, Research, Emergent, Acquisition, Lipid, Messenger, PEGylation, IBM, Geography, Risk, Fresenius (company), Fujifilm, Triglyceride, Element, MicroRNA, Acuitas Therapeutics, Vaccine

This in turn will drive the market growth of lipid nanoparticle manufacturing market during the forecast period.

Key Points: 
  • This in turn will drive the market growth of lipid nanoparticle manufacturing market during the forecast period.
  • The report features an extensive study of the current market landscape, market size and future opportunities within the lipid nanoparticle manufacturing market, during the given forecast period.
  • Key takeaways of the lipid nanoparticle manufacturing (services and technologies) market report are briefly discussed below.
  • An in-depth analysis of the factors that can impact the growth of lipid nanoparticle manufacturing market.

One Biosciences Partners With AP-HP to Launch a Single-cell Research Project on a Rare Kidney Disease

Retrieved on: 
Friday, November 10, 2023
Research, Assistance Publique–Hôpitaux de Paris, Transplant, AP-HP, Kidney disease, Disease, AI, A.I, Patient, Medicine, Creative Biolabs, Heart, Partnership, Syndrome, Biomarker, Sorbonne University, Hospital, Silla, Curie Institute (Paris), Single-cell analysis, Pharmaceutical industry, News

PARIS, Nov. 10, 2023 (GLOBE NEWSWIRE) -- One Biosciences, a biotech company leveraging the power of single-cell analysis and A.I.

Key Points: 
  • PARIS, Nov. 10, 2023 (GLOBE NEWSWIRE) -- One Biosciences, a biotech company leveraging the power of single-cell analysis and A.I.
  • A condition characterized by a gradual loss of kidney function over time, this particular disease has no viable therapeutic option to date and transplantation is often the only alternative, despite frequent relapses.
  • One Biosciences will leverage the data to identify new therapeutic targets in this rare kidney disease in order to develop precision medicines and biomarkers of a relapse of the disease via its discovery platform.
  • This is an important milestone, and I'd like to thank our partners for their commitment," said Hedi Ben Brahim, CEO of One Biosciences.

EQS-News: Evotec SE reports results for the first nine months 2023 and provides corporate update

Retrieved on: 
Thursday, December 14, 2023
Growth, Bridge, Drug discovery, Evotec, EVO, Novo Nordisk, Mass General Brigham, Biomarker, ISIN, Research, Frankfurt Stock Exchange, MDAX, Creative Biolabs, Yale University, Harvard University, EBITDA, MBC, Match point, LabCentral, Pharmaceutical industry, Arms industry, Fine chemical, Silviculture

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced the financial results and corporate updates for the first nine months 2023.

Key Points: 
  • Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced the financial results and corporate updates for the first nine months 2023.
  • Costs of € 43.9 m were incurred in 2023 as a direct result of the cyber-incident in early April, including additional external expenditures and internal recovery contributions.
  • In response to the criminal cyber-attack, Evotec took immediate action to contain and remediate the attack by taking its external-facing systems offline.
  • This was deemed necessary to protect all the Company’s partners and stakeholders and meant Evotec could ensure that the integrity of scientific data remained unaffected.

In Vitro Toxicology Testing Market Worth $17.1 billion | MarketsandMarkets

Retrieved on: 
Friday, October 27, 2023
MEA, Creative Biolabs, Eurofins Scientific, Pharmacology, Promega, Catalent, Patent, Intertek, Islamic finance products, services and contracts, Food, Charles River Laboratories, LATAM, Toxicology, Genetics, Absorption, Acquisition, Tissue engineering, Maintenance, Research, Protein, Phototoxicity, Software, Metabolism, Drug development, SGS, Growth, Thermo Fisher Scientific, Marketing, Merck Group, Agilent Technologies, Animal, Gene, Corrosion, Safety, Investment, Labcorp, Toxicity, Chemical safety, ADME, Medical device, Pharmaceutical industry, Fine chemical

By product and service, the In vitro toxicology testing market has been further categorized as consumables, assays, equipment, software, and services.

Key Points: 
  • By product and service, the In vitro toxicology testing market has been further categorized as consumables, assays, equipment, software, and services.
  • In 2022, the ADME segment accounted for the largest share of the in vitro toxicology testing market.
  • The pharmaceutical & biopharmaceutical segment accounted for the largest share of the industry segment in the in vitro toxicology testing market in 2022.
  • In 2022, the pharmaceutical & biopharmaceutical industry segment accounted for the largest share of the in vitro toxicology testing market.

In Vitro Toxicology Testing Market Worth $17.1 billion | MarketsandMarkets

Retrieved on: 
Friday, October 27, 2023
MEA, Creative Biolabs, Eurofins Scientific, Pharmacology, Promega, Catalent, Patent, Intertek, Islamic finance products, services and contracts, Food, Charles River Laboratories, LATAM, Toxicology, Genetics, Absorption, Acquisition, Tissue engineering, Maintenance, Research, Protein, Phototoxicity, Software, Metabolism, Drug development, SGS, Growth, Thermo Fisher Scientific, Marketing, Merck Group, Agilent Technologies, Animal, Gene, Corrosion, Safety, Investment, Labcorp, Toxicity, Chemical safety, ADME, Medical device, Pharmaceutical industry, Fine chemical

By product and service, the In vitro toxicology testing market has been further categorized as consumables, assays, equipment, software, and services.

Key Points: 
  • By product and service, the In vitro toxicology testing market has been further categorized as consumables, assays, equipment, software, and services.
  • In 2022, the ADME segment accounted for the largest share of the in vitro toxicology testing market.
  • The pharmaceutical & biopharmaceutical segment accounted for the largest share of the industry segment in the in vitro toxicology testing market in 2022.
  • In 2022, the pharmaceutical & biopharmaceutical industry segment accounted for the largest share of the in vitro toxicology testing market.

EQS-News: Evotec SE: Launch of partnering agreement to strengthen biotech innovators in shared R&D economy

Retrieved on: 
Wednesday, September 27, 2023
Partnership, MDAX, Frankfurt Stock Exchange, Medication, Research, Patient, MBC, LabCentral, Drug discovery, ISIN, Ecosystem, Creative Biolabs, Safety, EVO, Fine chemical, Pharmaceutical industry

LabCentral / BioLabs / MBC BioLabs offers laboratory and office spaces for over 400 start-ups comprising approximately 3,500 scientists and entrepreneurs, giving Evotec direct access to promising research of biotech companies across the US, France and Germany.

Key Points: 
  • LabCentral / BioLabs / MBC BioLabs offers laboratory and office spaces for over 400 start-ups comprising approximately 3,500 scientists and entrepreneurs, giving Evotec direct access to promising research of biotech companies across the US, France and Germany.
  • Dr Matthias Evers, Chief Business Officer of Evotec, commented: “The collaboration with LabCentral / BioLabs / MBC BioLabs is closely aligned with our mission ‘Together for Medicines that Matter’.
  • Our goal has always been to empower brilliant entrepreneurs within a thriving ecosystem that fosters innovation, collaboration, and ultimately, success.
  • Evotec’s shared R&D platform dovetails with our shared lab co-working space, furthering this mission.”
    No financial terms of the agreement were disclosed.

NMPA and FDA Approved the First-in-Human Clinical Trial Applications to Evaluate LBL-034, An Anti-GPRC5D/CD3 Bispecific Antibody Developed by Leads Biolabs, in Relapsed/Refractory Multiple Myeloma

Retrieved on: 
Monday, July 31, 2023
Life, Marketing, Multiple myeloma, Immunomodulatory imide drug, Cancer, Trial of the century, Creative Biolabs, Investigational New Drug, Patient, Risk, National Medical Products Administration, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, NMPA, Food, Safety, Pharmaceutical industry

This study aims to evaluate the safety and tolerability of LBL-034, determine the recommended Phase II dose and assess its efficacy in patients with multiple myeloma.

Key Points: 
  • This study aims to evaluate the safety and tolerability of LBL-034, determine the recommended Phase II dose and assess its efficacy in patients with multiple myeloma.
  • "Despite recent progress and continuous advancements in multiple myeloma, the time between recurrences has been steadily decreasing, particularly as the number of treatment lines increases.
  • This ultimately leads to emergence of relapsed or refractory multiple myeloma, reaffirming its status as an incurable malignant tumor that poses a serious threat to human life.
  • We adhere to our tradition of innovation and aim to deliver an important, novel and effective treatment option for patients with poor prognosis of relapsed/refractory multiple myeloma."

High-Throughput Screening (HTS) Market worth $44.5 billion | MarketsandMarkets

Retrieved on: 
Wednesday, July 5, 2023
Aurora, Bio-Rad Laboratories, Charles River Laboratories, BMG, Corning Inc., Drug development, Therapy, Crown Bioscience International, Czech Republic, Innovative Interstellar Explorer, Product-service system, Agriculture, Disease resistance, High-throughput screening, Rest of the world in sports and games, Merck Group, Research, HTS, Gesellschaft mit beschränkter Haftung, Danaher Corporation, Creative Biolabs, Promega, PerkinElmer, Translational research, Agilent Technologies, Drug discovery, Robotics, Health, Automation, Fine chemical, Pharmaceutical industry, Compact Disc manufacturing, Retail

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=134981950

Key Points: 
  • Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=134981950
    High-Throughput Screening (HTS) Market Advantages:
    Accelerated Drug Discovery: High-throughput screening (HTS) expedites the drug discovery process by quickly screening a large number of compounds against specific targets.
  • Target-specific Screening: HTS enables researchers to target specific molecular pathways or cellular functions, allowing for more focused screening.
  • High-Throughput Screening Market- Report Highlights:
    Refinements in the segments of the global high-throughput screening market:
    Company profiles give a glimpse of the key players in the market with respect to business overviews, financials, product offerings, and recent developments.
  • The biochemical screening and life sciences research segments were newly added to the application chapter of the current edition of the high-throughput screening market report.

High-Throughput Screening (HTS) Market worth $44.5 billion | MarketsandMarkets

Retrieved on: 
Wednesday, July 5, 2023
Aurora, Bio-Rad Laboratories, Charles River Laboratories, BMG, Corning Inc., Drug development, Therapy, Crown Bioscience International, Czech Republic, Innovative Interstellar Explorer, Product-service system, Agriculture, Disease resistance, High-throughput screening, Rest of the world in sports and games, Merck Group, Research, HTS, Gesellschaft mit beschränkter Haftung, Danaher Corporation, Creative Biolabs, Promega, PerkinElmer, Translational research, Agilent Technologies, Drug discovery, Robotics, Health, Automation, Fine chemical, Pharmaceutical industry, Compact Disc manufacturing, Retail

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=134981950

Key Points: 
  • Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=134981950
    High-Throughput Screening (HTS) Market Advantages:
    Accelerated Drug Discovery: High-throughput screening (HTS) expedites the drug discovery process by quickly screening a large number of compounds against specific targets.
  • Target-specific Screening: HTS enables researchers to target specific molecular pathways or cellular functions, allowing for more focused screening.
  • High-Throughput Screening Market- Report Highlights:
    Refinements in the segments of the global high-throughput screening market:
    Company profiles give a glimpse of the key players in the market with respect to business overviews, financials, product offerings, and recent developments.
  • The biochemical screening and life sciences research segments were newly added to the application chapter of the current edition of the high-throughput screening market report.

The U.S. FDA Approved the Phase I/II Clinical Trial Application to Evaluate LBL-033, An Anti-MUC16/CD3 Bispecific Antibody Developed by Leads Biolabs, in Advanced Solid Tumors Including Ovarian Cancer

Retrieved on: 
Friday, June 16, 2023
CD3, Food and Drug Administration, Clinical trial, Cancer, Pharmacokinetics, MUC16, Immunotherapy, Trial of the century, Creative Biolabs, Cytokine release syndrome, Patient, Phase, FDA, Ovarian cancer, IND, Safety, Pharmaceutical industry

At present, no antibody product targeting MUC16 has been approved for marketing both inside and outside China.

Key Points: 
  • At present, no antibody product targeting MUC16 has been approved for marketing both inside and outside China.
  • The study is a multicenter, open-label, dose-escalation and expansion phase Ⅰ/Ⅱ clinical study.
  • The phase Ⅰ part aims to evaluate the safety, tolerability, and pharmacokinetics of LBL-033 for the treatment of subjects with advanced malignancies, and to provide recommended doses for subsequent clinical studies.
  • The primary objective of the Phase Ⅱ part is to evaluate the efficacy of LBL-033.